Association of Early Renal Dysfunction with Lipid Profile Parameters among Hypertensives in Kazakhstan

Alma Nurtazina1, Dana Kozhakhmetova2, Daulet Dautov3

  • 1Department of Epidemiology and Biostatistics, Semey Medical University, Semey 071400, Kazakhstan.

Insights

Apolipoprotein B is linked to early kidney dysfunction in hypertensive patients. This finding aids in predicting pre-chronic kidney disease (CKD) and cardiovascular disease (CVD) risk.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Biochemistry

Background:

  • Dyslipidemia is a key factor in chronic kidney disease (CKD) progression.
  • The role of lipids in early-stage CKD among hypertensive individuals remains under-investigated.
  • Hypertension is a major risk factor for CKD and cardiovascular disease (CVD).

Purpose of the Study:

  • To investigate the association between early renal dysfunction and lipid profile parameters in hypertensive patients in Kazakhstan.
  • To identify potential biomarkers for predicting pre-CKD in this population.
  • To assess the predictive value of Apolipoprotein B for early declines in estimated glomerular filtration rate (eGFR).

Main Methods:

  • Cross-sectional study involving 800 primary hypertensive patients.
  • Data collection included socio-demographics, lifestyle, anthropometrics, blood pressure, and Dietary Quality Score (DQS).
  • Laboratory analysis measured eGFR, Apolipoprotein B, Apolipoprotein A1, HDL-C, LDL-C, and TG; ROC analysis was performed.

Main Results:

  • A significant inverse linear association was found between eGFR and Apolipoprotein B (r = -0.23).
  • Apolipoprotein B demonstrated predictive power for eGFR decline (AUC = 0.62, adjusted AUC = 0.77).
  • Optimal Apolipoprotein B cutoff points for predicting pre-CKD were identified for males (1.05 g/L) and females (0.98 g/L).

Conclusions:

  • Apolipoprotein B is a potential early predictor of renal dysfunction in hypertensive patients.
  • Early identification of renal dysfunction using Apolipoprotein B can improve CVD risk estimation.
  • Findings support the integration of lipid profiles in monitoring hypertensive patients for pre-CKD.

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
232
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
163
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
230
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
44
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
166
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
102